Fudan University — CureCurrent

Published trials530

Recruiting shown60

Roles2

SourceClinicalTrials.gov

Clinical trials

60 shown

1-Week Versus 3-Week PBINCT07832279 · lead sponsor · 2026-10-01

Hypofractionated vs. Conventionally Fractionated Postmastectomy Radiotherapy After Implant-Based ReconstructionNCT07835139 · lead sponsor · 2026-10-01

Response-Adapted Omission of Nodal Boost In N3 Breast Cancer After Neoadjuvant Systemic TherapyNCT07829848 · lead sponsor · 2026-09-12

Omission of Adjuvant Radiotherapy in Young Low-Risk Ductal Carcinoma In Situ Following Breast-Conserving SurgeryNCT07762924 · lead sponsor · 2026-09-01

Omission of Adjuvant Radiotherapy in Low- and Intermediate-Risk Ductal Carcinoma In Situ After Breast-Conserving SurgeryNCT07762885 · lead sponsor · 2026-07-01

A Phase II Clinical Study of the Efficacy and Safety of Culmerciclib Rechallenge in HR-positive, HER2-negative Breast Cancer Patients With Resistance to First-line Endocrine Therapy.NCT07666555 · lead sponsor · 2026-06-06

Real-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Breast CancerNCT07551050 · lead sponsor · 2026-05-15

Association Between Screening Behaviors and Lung Cancer SpectrumNCT07626177 · lead sponsor · 2026-05-14

Opportunistic Breast Cancer Screening Using Non-Contrast Chest CTNCT07557654 · lead sponsor · 2026-05-06

Artificial Intelligence Model-Guided Neoadjuvant Anti-HER2 Targeted TherapyNCT07528716 · lead sponsor · 2026-05-06

Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLCNCT07554846 · lead sponsor · 2026-05-01

CDK4/6 Inhibitors Intensification for Chemotherapy Omission in Small Size High-risk ER-positive Breast Cancer（Cinnamon）NCT07432178 · lead sponsor · 2026-04-03

Trastuzumab Deruxtecan Plus ivonescImab for Hormone Receptor-positive HER2 Negative Advanced Breast Cancer StudyNCT07647016 · lead sponsor · 2026-04-01

Air Purifier Use and Respiratory Health in COPD PatientsNCT07505602 · lead sponsor · 2026-03-30

A Phase II Clinical Study of Multimodal Ablation Combined With Systemic Drug Therapy for Advanced Solid Tumors.NCT06889610 · lead sponsor · 2026-03-30

Digital Mind-Body Therapy for Neoadjuvant Breast CancerNCT07541664 · lead sponsor · 2026-03-25

Olive Oil Before Lung Cancer Surgery to Prevent ChylothoraxNCT07807696 · lead sponsor · 2026-03-15

Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast CancerNCT07471776 · lead sponsor · 2026-03-11

SHR-1701 in Combination With Stereotactic Body Radiotherapy in mCRPCNCT07451795 · lead sponsor · 2026-03-02

Comparison of Serplulimab Versus Nivolumab in Neoadjuvant Therapy for Resectable Stage II-IIIA Squamous NSCLCNCT07398937 · lead sponsor · 2026-02-05

Study of Radiotherapy Combined With Cisplatin/Carboplatin, Adebrelimab and Bevacizumab in the Treatment of TNBC-BM.NCT07638852 · lead sponsor · 2026-02-02

Psychological State, Immunotherapy Response, and Multi-Omics Signatures in TNBCNCT07290153 · lead sponsor · 2026-01-01

Sac-TMT Combined With Bevacizumab in TNBC With Brain MetastasesNCT07623577 · lead sponsor · 2026-01-01

ctDNA-guided Treatment Decision-makingNCT07394218 · lead sponsor · 2025-12-24

Station 4L Lymph Node Dissection Versus No Dissection in Clinical Stage I Solid Nodule-Type Invasive NSCLCNCT07801430 · lead sponsor · 2025-12-15

Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastasesNCT07469267 · lead sponsor · 2025-10-24

T-DXd With or Without Bevacizumab for HER2-low Breast Cancer With Brain MetastasisNCT07150208 · lead sponsor · 2025-10-20

SKB264 Plus Inetetamab in HER2-Positive Metastatic Breast Cancer Patients Progressing After T-DXd TreatmentNCT07182721 · lead sponsor · 2025-09-30

An Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard TherapyNCT07117630 · lead sponsor · 2025-09-25

T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain MetastasisNCT07152782 · lead sponsor · 2025-09-24

The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive ImpairmentNCT07395960 · lead sponsor · 2025-09-01

Cryoablation Combined With Lenvatinib Plus QL1706 (Iparomlimab/Tuvonralimab) in Patients With Advanced Intrahepatic CholangiocarcinomaNCT07070700 · lead sponsor · 2025-08-20

A Randomized, Open-label, Multi-center Phase III Study Comparing the Efficacy of Oral Chemotherapy Combined With Trastuzumab Versus Paclitaxel Combined With Trastuzumab in the Adjuvant Treatment of HER2-positive, Lymph Node-negative Early Breast Cancer Patients(ORCHID-PLUS)NCT06992882 · lead sponsor · 2025-07-08

CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)NCT07019363 · lead sponsor · 2025-06-15

A Phase II Observational Clinical Study on the Relationship Between Cerebrospinal Fluid Drug Concentration and Efficacy of Trastuzumab Deruxtecan in Central Nervous System Metastatic Breast CancerNCT07653893 · lead sponsor · 2025-06-11

Granzyme B-PET: Predicting Immunotherapy Efficacy in TNBCNCT07705438 · lead sponsor · 2025-05-28

Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)NCT06943235 · lead sponsor · 2025-04-25

Phase I/II Study of Intrathecal/Ommaya T-DXd in HER2-Expressing Breast Cancer With Leptomeningeal/Brain MetastasesNCT07134153 · lead sponsor · 2025-04-18

Neoadjuvant SNF Precision Therapy Phase IIINCT06913777 · lead sponsor · 2025-04-08

Molecular Subtyping of Breast Cancer-derived Small Extracellular Vesicles (sEVs) to Predict Therapeutic EfficacyNCT07574749 · lead sponsor · 2025-04-07

Corticosteroids for Doxorubicin Liposome-Induced Hand-Foot-Skin ReactionsNCT07362914 · lead sponsor · 2025-03-07

Perioperative Immunotherapy for Resectable Limited-Stage SCLCNCT07109401 · lead sponsor · 2025-03-01

A Study of Sirolimus (Albumin-Bound) in Combination With Palbociclib and Fulvestrant for the Treatment of Advanced Breast CancerNCT06856200 · lead sponsor · 2025-02-28

The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung CancerNCT06738160 · lead sponsor · 2025-02-15

Pyrotinib and Trastuzumab Combined With Dalpiciclib Versus Combined With Docetaxel in Advanced HER2-Positive Breast CancerNCT07615751 · lead sponsor · 2025-02-12

Reverse HER2-negative Immune Resistant Breast CancerNCT06731140 · lead sponsor · 2025-02-12

Sunvozertinib Treatment in Untreated Advanced NSCLC With EGFR Uncommon MutationsNCT07117890 · lead sponsor · 2025-02-07

Capecitabine in Low Risk Triple Negative Breast CancerNCT06787339 · lead sponsor · 2025-01-20

Study on the Mechanism of Acquired Resistance of EntrectinibNCT07199959 · lead sponsor · 2025-01-15

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIsNCT06775743 · lead sponsor · 2025-01-15

Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast CancerNCT06637150 · lead sponsor · 2025-01-09

Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain MetastasisNCT06718933 · lead sponsor · 2025-01-08

AI-Enhanced Imaging in Population Breast Cancer ScreeningNCT07411443 · lead sponsor · 2025-01-01

BrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADCNCT06793332 · lead sponsor · 2024-12-17

The Association Between Age-related Peripheral Blood Components and Treatment Efficacy in Breast CancerNCT06718010 · lead sponsor · 2024-12-05

Artificial Intelligence-based Model for the Prediction of Occult Lymph Node Metastasis and Improvement of Clinical Decision-making in Non-small Cell Lung CancerNCT06684418 · lead sponsor · 2024-12-01

Ivonescimab in the Treatment of Multiple Advanced TumorsNCT06683846 · lead sponsor · 2024-11-20

HER2-PET: Predicting T-DXd Efficacy and HER2 HeterogeneityNCT07586215 · lead sponsor · 2024-11-11

All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II TrialNCT06636981 · lead sponsor · 2024-11-04

Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast CancerNCT06649331 · lead sponsor · 2024-10-21

Sponsor roles

lead sponsor465

collaborator65

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.